Background: Alopecia can be a manifestation of mycosis fungoides (MF) and Sézary syndrome (SS), but the prevalence is unknown.
Objective: We sought to describe the clinicopathologic presentation and molecular features of alopecia in patients with MF/SS.
Methods: A retrospective chart review of a prospectively collected MF/SS database was used to identify patients with alopecia. The National Alopecia Areata Registry was used to identify patients with self-reported cutaneous T-cell lymphoma.
Results: Among 1550 patients with MF/SS, 38 patients with patchy, total-scalp, or universal alopecia were identified. Thirteen of 38 (34%) had patchy alopecia clinically identical to alopecia areata. Scalp biopsy specimens were available in 5 of the 13 patients. Specimens from 4 patients had atypical T lymphocytes within the follicular epithelium or epidermis, and that from two patients had a histology of follicular mucinosis. The remaining 25 of 38 (66%) patients with MF/SS included 20 with alopecia within discreet patch/plaque or follicular lesions of MF and 5 with total-body hair loss, which presented only in those with generalized erythroderma and SS.
Limitations: This was a retrospective study done at one cancer center. Biopsy specimens of alopecia were not available for every patient.
Conclusions: Alopecia was observed in 2.5% of patients with MF/SS, with alopecia areata-like patchy loss in 34% and alopecia within MF lesions in 66%.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2009.12.056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.
Indian Dermatol Online J
December 2024
Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
Background: Inflammatory dermatological conditions, including psoriasis, lichen planus, eczema, and alopecia areata, are frequently accompanied by nail findings and can have a significant impact on quality of life. Biologic and small-molecule medications have been approved over the past several decades in treating patients with these inflammatory nail disorders. They may be used in conjunction with longstanding mainstays of treatment (topical and intralesional corticosteroids, topical vitamin D3 analogs).
View Article and Find Full Text PDFUnexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights.
Cureus
December 2024
Department of Dermatology and Venereology, Zhongnan Hospital of Wuhan University, Wuhan, CHN.
Alopecia universalis (AU) is a severe form of alopecia areata characterized by the complete loss of scalp and body hair. While Janus kinase (JAK) inhibitors like baricitinib have shown promise in promoting hair regrowth in severe cases of AU, unexpected side effects, such as hair depigmentation, have not been widely reported. We present the case of a young male with AU who experienced progressive and extensive whitening of his scalp and body hair following treatment with baricitinib.
View Article and Find Full Text PDFEyelash trichomegaly complicating pembrolizumab for colorectal cancer.
J Oncol Pharm Pract
January 2025
Department of Oncology, Evaggelismos General Hospital, Athens, Greece.
Introduction: Pembrolizumab is an immune checkpoint inhibitor widely administered for the treatment of various malignancies. Despite its effectiveness, its distinctive mechanism of action may lead to immune-related adverse events, most frequently affecting cutaneous tissues. Hair-related adverse events, although uncommon, include conditions such as alopecia areata and alterations in hair texture or type.
View Article and Find Full Text PDFDiscovery of Orally Available Prodrugs of Itaconate and Derivatives.
J Med Chem
January 2025
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague 160 00, Czech Republic.
Itaconate, an endogenous immunomodulator from the tricarboxylic acid (TCA) cycle, shows therapeutic effects in various disease models, but is highly polar with poor cellular permeability. We previously reported a novel, topical itaconate derivative, SCD-153, for the treatment of alopecia areata. Here, we present the discovery of orally available itaconate derivatives for systemic and skin disorders.
View Article and Find Full Text PDFLong-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.
J Eur Acad Dermatol Venereol
January 2025
Pfizer Inc, Paris, France.
Background: ALLEGRO-LT is an ongoing, long-term, open-label, multicentre, phase 3 study of ritlecitinib in adults and adolescents with alopecia areata (AA).
Objectives: To evaluate ritlecitinib safety and efficacy through Month 24 in patients with AA and ≥25% scalp hair loss.
Methods: ALLEGRO-LT enrolled rollover patients who previously received study intervention in either ALLEGRO phase 2a or 2b/3 studies and de novo patients who had not received treatment in either study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!